Halozyme Therapeutics
(NASDAQ) HALO
Halozyme Therapeutics Financials at a Glance
Market Cap
$8.44B
Revenue (TTM)
$1.51B
Net Income (TTM)
$348.84M
EPS (TTM)
$2.78
P/E Ratio
25.59
Dividend
$0.00
Beta (Volatility)
0.77 (Low)
Dividend
$0.00
Beta (Volatility)
0.77 (Low)
Price
$71.15
Volume
62,467
Open
$70.27
Price
$71.15
Volume
62,467
Open
$70.27
Previous Close
$71.15
Daily Range
$69.84 - $71.87
52-Week Range
$51.06 - $82.22
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
0.77 (Low)
Price
$71.15
Volume
62,467
Open
$70.27
Previous Close
$71.15
Daily Range
$69.84 - $71.87
52-Week Range
$51.06 - $82.22
Estimated Earnings Date
Aug 4, 2026
HALO News
HALO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Halozyme Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
423
CEO
Helen I. Torley, MD
Website
www.halozyme.comHeadquarters
San Diego, CA 92121, US
HALO Financials
Key Financial Metrics (TTM)
Gross Margin
76.93%
Operating Margin
56.96%
Net Income Margin
23.13%
Return on Equity
126.27%
Return on Capital
37.25%
Return on Assets
13.05%
Earnings Yield
3.91%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$8.44B
Shares Outstanding
118.61M
Volume
62.47K
Avg. Volume
1.65M
Financials (TTM)
Gross Profit
$1.16B
Operating Income
$859.28M
EBITDA
$623.82M
Operating Cash Flow
$677.42M
Capital Expenditure
-$9.76M
Free Cash Flow
$667.65M
Cash & ST Invst.
$318.62M
Total Debt
$2.14B
Halozyme Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$376.71M
+42.2%
Gross Profit
$267.96M
+34.9%
Gross Margin
71.13%
N/A
Market Cap
$8.44B
N/A
Market Cap/Employee
$24.11M
N/A
Employees
350
N/A
Net Income
$150.05M
+27.1%
EBITDA
$219.57M
+30.1%
Quarterly Fundamentals
Total Cash
$318.62M
-57.4%
Total Debt
$2.14B
+42.3%
Accounts Receivable
$457.99M
+50.3%
Inventory
$155.47M
-5.7%
Long Term Debt
$1.94B
+28.4%
Short Term Debt
$208.74M
N/A
Return on Assets
13.05%
N/A
Return on Invested Capital
37.21%
N/A
Free Cash Flow
$176.34M
+15.0%
Operating Cash Flow
$180.08M
+16.8%